SCHEMBL24257760

SCHEMBL24257760

Cc1c(-c2cnn(CC(C)C)c2)cnc(C(=O)O)c1OCc1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 1/20 0.41
NAMPT P43490 1/20 0.40
PDK2 Q15119 3/20 0.40
ADORA2B P29275 3/20 0.37
ADORA3 P0DMS8 2/20 0.37
ACHE P22303 2/20 0.37
ADORA2A P29274 2/20 0.36
ADORA1 P30542 2/20 0.36
PTGER1 P34995 1/20 0.36
ALKBH1 Q13686 2/20 0.36
AXL P30530 1/20 0.35
TYRO3 Q06418 1/20 0.35
MERTK Q12866 1/20 0.35
GLRA1 P23415 1/20 0.35
PTPN1 P18031 1/20 0.35
KDR P35968 1/20 0.35
AURKB Q96GD4 1/20 0.35
RET P07949 1/20 0.35
PIK3CD O00329 1/20 0.35
MAPK1 P28482 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24257808 0.86 PDK2 (0.39) JAK2PDK2PTGER1ALKBH1GLRA1
SCHEMBL24257785 0.85 KMT2A (0.42) NAMPT
SCHEMBL24257499 0.82 GRM4 (0.50) ALKBH1MAPK1
SCHEMBL24257579 0.82 RET (0.40) JAK2NAMPTPDK2ADORA2BADORA3
Nitrous Acid SCHEMBL29248888 0.80 GRM4 (0.48) ALKBH1MAPK1
SCHEMBL24257533 0.79 EGLN1 (0.46) ALKBH1
SCHEMBL24257566 0.78 GRM4 (0.44) ALKBH1
SCHEMBL24257759 0.77 KDM4E (0.42) PTGER1PTPN1
Nitrous Acid SCHEMBL29248972 0.77 EGLN1 (0.44) ALKBH1
SCHEMBL24257743 0.76 CYP11B1 (0.50)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
CN-116670131-A PHD inhibitor compounds, compositions, and methods of use 阿克比治疗有限公司 2023-08-29 CN disclosed
EP-4196466-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE Akebia Therapeutics Inc. (US) 2023-06-21 EP disclosed
WO-2022036188-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE HIF1AN, EGLN3, PHF20 JAK2 136/4885NAMPT 2703/4885PDK2 762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.